Find policies, billing codes, payers, states, and providers
HCPCS Level II J2786: Reslizumab Injection, 1 mg
HCPCS Level II code J2786 represents a per-milligram billing unit for reslizumab injection, a monoclonal antibody administered as an outpatient injectable biologic therapy. Nationally, biologic injectables like reslizumab are significant due to their clinical role in targeted treatment pathways and their impact on specialty drug spending and site-of-service utilization. This publication covers commercial and public payers commonly involved in coverage and payment for injectable biologics, including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find an overview of what J2786 denotes clinically and operationally, typical sites of service where reslizumab is administered, and the payer landscape addressed in the analysis. The report also outlines benchmarks and reimbursement context, common modifier usage and billing considerations, and clinical context for the medication’s use as an outpatient injectable. Where specific input data is not provided, this summary indicates that such items are not available in the input.
Customize your policy alerts
Sign up for hcpcs J2786 policy alerts
Get alerted when payer policies referencing J2786 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J2786 describes the administration of reslizumab by injection, billed per 1 mg unit. The service type is an injectable biologic therapy used for targeted treatment. The typical site of service for this medication is an outpatient infusion or injection setting, such as an infusion center, outpatient clinic, or physician office.